CAT upholds pay-for-delay decision but trims penalties
The UK’s specialist competition tribunal has confirmed that GlaxoSmithKline and three generic drugmakers broke competition rules by entering into pay-for-delay agreements for the antidepressant drug paroxetine – but slashed the original fines by £27 million.
To read more
Subscribe to Global Competition Review
Subscribe to unlock unlimited access
Get news, unique commentary, expert analysis and essential resources from the Global Competition Review experts.